The companies will jointly commercialize and distribute the assay to support the SARS-CoV-2 vaccine development community. They anticipate the kits will be available in early August.
The enzyme-linked immunosorbent assay (ELISA) will measure the presence or absence of anti-COVID-19 antibodies and titer levels of antibodies. It will use two virus antigens: a full-length spike protein and a receptor-binding domain.
Kantaro Biosciences is the commercial arm of Mount Sinai Health System.
Copyright © 2020 scienceboard.net